{"prompt": "['EudraCT number: 2016-005228-27', 'IRAS ID Number: 213113', 'Page 66 of 74', '23.7 Appendix 7 - Safety reporting flowchart', 'Adverse Event (AE)', 'Did the event meet any of the serious criteria?', '- Resulted in death', 'AE/Adverse Reaction', '- Life-threatening', 'Record all AE/AR data on the appropriate', '- Required inpatient hospitalisation or prolongation', 'No', 'CRF and send to CCTU-CT within the', 'of existing hospitalisation', 'CRF due date', '- Persistent or significant disability/incapacity', '- Congenital anomaly/birth defect', '- Important medical event/Medically important', 'Exempt Event', 'Yes', 'Yes', 'Record on the appropriate CRF and send', 'to CCTU-CT within the CRF due date', 'Was the event specified in the protocol as being', 'exempt from expedited reporting?', 'No', 'Serious Adverse Event', 'No - Unlikely or', 'Record on an SAE form. Notify CCTU-CT', 'Not related', 'immediately (within 24 hours of becoming', 'Causal relationship to protocol medication?', 'aware of the event).', 'Yes - Definitely,', 'Probably or Possibly', 'related', 'Serious Adverse Reaction', 'Record on an SAE form. Notify CCTU-CT', 'Was the SAE one of the recognised undesirable', 'immediately (within 24 hours of becoming', 'Yes - Expected', 'effects of the trial medication according to the', 'aware of the event).', 'Reference Safety Information?', 'No - Unexpected', 'SUSAR', 'Telephone the CCTU-CT immediately.', 'Record on an SAE form and submit to the', 'CCTU-CT immediately (within 24 hours of', 'becoming aware of the event)', 'INTERIM', 'Protocol Version: V1.1 Version Date: 21 September 2017']['EudraCT number: 2016-005228-27', 'IRAS ID Number: 213113', 'Page 67 of 74', '23.8 Appendix 8 - Reference Safety Information (RSI)', 'Data taken from:', 'Debrafenib - Summary of Product Characteristics - updated 19 April 2017.', 'Trametinib - Summary of Product Characteristics - updated 19April 2017.', 'Tabulated summary of adverse reactions', 'ADRs which were reported are listed below by MedDRA body system organ class and by', 'frequency. The following convention has been utilised for the classification of', 'frequency:', 'Very common 1/10', 'Common >1/100 to <1/10', 'Uncommon 1/1,000 to <1/100', 'Rare >1/10,000 to <1/1,000', 'Not known (cannot be estimated from the available data)', 'For SUSAR reporting use the following tables to determine expectedness:', 'Table 1: To determine expectedness in relation to dabrafenib in patients taking', 'dabrafenib monotherapy', 'Table 2: To determine expectedness in relation to trametinib in patients taking', 'trametinib monotherapy', 'Table 3: To determine expectedness in relation to dabrafenib in patients taking', 'dabrafenib in combination with trametinib', 'Table 4: To determine expectedness in relation to trametinib in patients taking', 'trametinib in combination with dabrafenib', 'INTERIM', 'Protocol Version: V1.1 Version Date: 21 September 2017']['EudraCT number: 2016-005228-27', 'IRAS ID Number: 213113', 'Page 68 of 74', 'Table 1:Adverse reactions reported in the integrated safety population of', 'dabrafenib monotherapy (n=578)', 'System Organ Class', 'Frequency (all grades)', 'Adverse Reactions', 'Neoplasms benign,', 'Very common', 'Papilloma', 'malignant and unspecified', 'Common', 'Cutaneous squamous cell', '(including cysts and', 'carcinoma', 'polyps)', 'Seborrhoeic keratosis', 'Acrochordon (skin tags)', 'Basal cell carcinoma', 'Uncommon', 'New primary lesions', 'Immune system disorders', 'Uncommon', 'Hypersensitivity', 'Metabolism and nutrition', 'Very common', 'Decreased appetite', 'disorders', 'Common', 'Hypophosphataemia', 'Hyperglycaemia', 'Nervous system disorders', 'Very common', 'Headache', 'Eye disorders', 'Uncommon', 'Uveitis', 'Respiratory, thoracic and', 'Very common', 'Cough', 'mediastinal disorders', 'Gastrointestinal disorders', 'Very common', 'Nausea', 'Vomiting', 'Diarrhoea', 'Common', 'Constipation', 'Uncommon', 'Pancreatitis', 'Skin and subcutaneous', 'Very common', 'Hyperkeratosis', 'tissue', 'Alopecia', 'disorders', 'Rash', 'Palmar-plantar', 'erythrodysaesthesia', 'Common', 'Dry skin', 'Pruritus', 'Actinic keratosis', 'Skin lesion', 'Erythema', 'Photosensitivity Reaction', 'Uncommon', 'Panniculitis', 'Musculoskeletal and', 'Very common', 'Arthralgia', 'connective', 'Myalgia', 'tissue disorders', 'Pain in extremity', 'Renal and urinary', 'Uncommon', 'Renal failure, acute renal', 'disorders', 'failure', 'Nephritis', 'General disorders and', 'Very common', 'Pyrexia', 'administration site', 'Fatigue', 'conditions', 'Chills', 'Asthenia', 'Common', 'Influenza-like illness', 'INTERIM', 'Protocol Version: V1.1 Version Date: 21 September 2017']\n\n###\n\n", "completion": "END"}